These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23378065)

  • 1. Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
    Haynes BP; Viale G; Galimberti V; Rotmensz N; Gibelli B; A'Hern R; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2013 Feb; 138(1):157-65. PubMed ID: 23378065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.
    Haynes BP; Viale G; Galimberti V; Rotmensz N; Gibelli B; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2014 Nov; 148(2):327-35. PubMed ID: 25367875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
    Haynes BP; Ginsburg O; Gao Q; Folkerd E; Afentakis M; Buus R; Quang LH; Thi Han P; Khoa PH; Dinh NV; To TV; Clemons M; Holcombe C; Osborne C; Evans A; Skene A; Sibbering M; Rogers C; Laws S; Noor L; Smith IE; Dowsett M
    NPJ Breast Cancer; 2019; 5():42. PubMed ID: 31754627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
    Haynes BP; Schuster G; Buus R; Alataki A; Ginsburg O; Quang LH; Han PT; Khoa PH; Van Dinh N; Van To T; Clemons M; Holcombe C; Osborne C; Evans A; Skene A; Sibbering M; Rogers C; Laws S; Noor L; Cheang MCU; Cleator SJ; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2021 Nov; 190(2):295-305. PubMed ID: 34524591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
    Dunbier AK; Anderson H; Ghazoui Z; Folkerd EJ; A'hern R; Crowder RJ; Hoog J; Smith IE; Osin P; Nerurkar A; Parker JS; Perou CM; Ellis MJ; Dowsett M
    J Clin Oncol; 2010 Mar; 28(7):1161-7. PubMed ID: 20124184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
    Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
    Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR; Larionov A
    Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.
    Ghosh MG; Thompson DA; Weigel RJ
    Cancer Res; 2000 Nov; 60(22):6367-75. PubMed ID: 11103799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle.
    Weimer DA; Donegan WL
    Breast Cancer Res Treat; 1987 Dec; 10(3):273-8. PubMed ID: 3447646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
    Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
    Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.
    Horimoto Y; Arakawa A; Tanabe M; Kuroda K; Matsuoka J; Igari F; Himuro T; Yoshida Y; Tokuda E; Shimizu H; Hino O; Saito M
    J Clin Pathol; 2015 Oct; 68(10):825-9. PubMed ID: 26060263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
    Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
    Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
    Chic N; Schettini F; Brasó-Maristany F; Sanfeliu E; Adamo B; Vidal M; Martínez D; Galván P; González-Farré B; Cortés J; Gavilá J; Saura C; Oliveira M; Pernas S; Martínez-Sáez O; Soberino J; Ciruelos E; Carey LA; Muñoz M; Perou CM; Pascual T; Bellet M; Prat A
    EBioMedicine; 2021 Jul; 69():103451. PubMed ID: 34161883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.
    Tan S; Ding K; Li R; Zhang W; Li G; Kong X; Qian P; Lobie PE; Zhu T
    Breast Cancer Res; 2014 Apr; 16(2):R40. PubMed ID: 24735615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
    Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
    Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients.
    Wanifuchi-Endo Y; Asano T; Kondo N; Hato Y; Dong Y; Hisada T; Nishikawa S; Kato H; Takahashi S; Okuda K; Yamashita H; Toyama T
    Jpn J Clin Oncol; 2019 Jan; 49(1):12-21. PubMed ID: 30395264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.